Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024
USPTO grants additional method of use patent for ganaxolone in TSC
.
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript November 7, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.67. Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions]. And now, it is my pleasure to introduce your host, Sonya […]
RADNOR, Pa. (BUSINESS WIRE) $MRNS #MarinusPharma Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m..